| Reference |
 |
Advanced TCC: CALGB 90601
| Title |
|
A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY COMPARING GEMCITABINE, CISPLATIN, AND BEVACIZUMAB TO GEMCITABINE, CISPLATIN, AND PLACEBO IN PATIENTS WITH ADVANCED TRANSITIONAL CELL CARCINOMA
| Description |
|
ELIGIBILITY
- Histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract with progressive metastatic or locally advanced disease (T4B, N2, N3, or M1) and must not be candidates for potentially curative surgery or radiotherapy.
- No history of peritoneal carcinomatosis
- No known brain metastases
TREATMENT
Arm A
- Patients receive Gemcitabine, Cisplatin, and Placebo
Arm B
- Patients receive Gemcitabine, Cisplatin, and Bevacizumab
After completion of study therapy, patients are followed up periodically for up to 7 years.
| Additional Info |
|
On the web: http://www.clinicaltrials.gov/ct2/search
|
